Global Blood Therapeutics (GBT) Price Target Raised to $90.00

Global Blood Therapeutics (NASDAQ:GBT) had its price objective lifted by SunTrust Banks to $90.00 in a report published on Tuesday, The Fly reports. SunTrust Banks currently has a positive rating on the stock. SunTrust Banks also issued estimates for Global Blood Therapeutics’ FY2018 earnings at ($3.45) EPS, FY2020 earnings at ($3.41) EPS, FY2020 earnings at ($3.12) EPS, FY2021 earnings at ($1.53) EPS, FY2021 earnings at ($2.32) EPS, FY2022 earnings at ($0.23) EPS and FY2022 earnings at $1.29 EPS.

Several other equities research analysts have also commented on GBT. Oppenheimer set a $82.00 price objective on shares of Global Blood Therapeutics and gave the company a buy rating in a research note on Monday, December 3rd. BidaskClub upgraded shares of Global Blood Therapeutics from a strong sell rating to a sell rating in a research note on Wednesday, August 8th. ValuEngine upgraded shares of Global Blood Therapeutics from a buy rating to a strong-buy rating in a research note on Thursday, October 18th. Cantor Fitzgerald set a $96.00 price objective on shares of Global Blood Therapeutics and gave the company a buy rating in a research note on Monday, December 3rd. Finally, HC Wainwright set a $150.00 price objective on shares of Global Blood Therapeutics and gave the company a buy rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Global Blood Therapeutics currently has an average rating of Buy and an average price target of $83.20.

Shares of NASDAQ GBT opened at $42.66 on Tuesday. Global Blood Therapeutics has a fifty-two week low of $30.15 and a fifty-two week high of $68.05. The stock has a market capitalization of $2.44 billion, a P/E ratio of -15.45 and a beta of 3.65.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Tuesday, November 6th. The company reported ($0.83) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.02. During the same quarter in the previous year, the business posted ($0.66) earnings per share. On average, equities analysts expect that Global Blood Therapeutics will post -3.36 earnings per share for the current year.

A number of large investors have recently bought and sold shares of GBT. Focused Wealth Management Inc purchased a new stake in shares of Global Blood Therapeutics during the 3rd quarter worth approximately $104,000. PNC Financial Services Group Inc. increased its stake in shares of Global Blood Therapeutics by 740.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the company’s stock worth $165,000 after purchasing an additional 3,835 shares during the last quarter. Rehmann Capital Advisory Group purchased a new stake in shares of Global Blood Therapeutics during the 3rd quarter worth approximately $165,000. Tiverton Asset Management LLC purchased a new stake in shares of Global Blood Therapeutics during the 2nd quarter worth approximately $166,000. Finally, Quantitative Systematic Strategies LLC purchased a new stake in shares of Global Blood Therapeutics during the 2nd quarter worth approximately $203,000.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Further Reading: Find a Trading Strategy That Works

The Fly

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply